Skip to content.

Aptose Biosciences completes Public Offering of Common Shares for US$74.2M

Date Closed

December 19, 2019

Lead Office

Québec City


74.20 Million USD

On December 19, 2019, Aptose Biosciences Inc. completed its previously announced underwritten public offering of 18,543,750 common shares at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering. Gross proceeds from the offering are approximately US$74.2 million.

Piper Jaffray & Co. acted as the sole active book-running manager and Canaccord Genuity acted as passive book-running manager for the Offering. Oppenheimer & Co. acted as lead manager and JonesTrading Institutional Services LLC acted as co-manager for the Offering.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Souliere that included Isabelle Nazon and David Martin.